Thermo Fisher Scientific Human IFN-alpha 2 (alpha 2b) Recombinant Protein

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

E. coli

Molecular weight

19.3 kDa

Class

Recombinant

Type

Protein

Purity

>95%

Endotoxin concentration

<1 EU/µg

Activity

EC50 ~ 1 U/mL; determined by use of the cytopathic effect inhibition assay described in [Rubinstein, S. et al. (1981). J. Virol. 37, 755-758]; [Familletti, P.C. et al. (1981). Methods in Enzymology, Vol. 78, 387-394]. The units are determined with respect to the international reference standard for human interferon alpha A (Hu-IFN-alpha-A) provided by the National Institutes of Health [see Pestka, S. (1986). Methods in Enzymology, Academic Press, New York 119, 14-23]. Unit of activity measured on bovine MDBK cells with vesicular stomatitis virus (VSV).

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

Lot-specific

Purification

purified

Storage buffer

PBS with 0.1% BSA

Contains

no preservative

Storage conditions

-80° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Dry ice

Product Specific Information

After receipt, the product may be stored at -20°C for short-term use (less than 6 months). For long-term storage, store the product at -70°C or below for retention of full activity. Thaw product vial by incubation in cold tap water until just thawed. Aliquot and refreeze unused contents to minimize effects of freeze thawing. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of product should be in buffers containing protein such as 0.1% BSA or tissue culture media with serum.

Target Information

Interferon alpha-2b is a cytokine that belongs to the type I interferon family and is encoded by a gene cluster on chromosome 9. It is produced in response to viral infection and plays a key role in the innate immune response, exhibiting potent antiviral, antiproliferative and immunomodulatory properties. Interferon alpha-2b binds to a plasma membrane receptor consisting of IFNAR1 and IFNAR2, which is expressed ubiquitously in the body and can thus act on virtually all cells. This cytokine is effective in reducing the symptoms and duration of the common cold, and has shown efficacy in treating various types of cancer, including hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is considered a hallmark of severe COVID-19, and a combination therapy involving interferon alpha-2b may be a potential therapeutic approach. IFNA2 has been associated with diseases such as Severe Covid-19 and Hepatitis B.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.